Trial site
Medical Center Intermedica Ltd.
Sofiya, 1680, BulgariaEU-13 widening countryNot linked to an institution yet
- 4running trials
- 11closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 25 trials
- Phase 2/32 trials
- Status
- Completed11 trials
- Recruiting4 trials
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company3 trials
- ACADIA Pharmaceuticals Inc.2 trials
- Boehringer Ingelheim International GmbH1 trial
- Cerevel Therapeutics LLC1 trial
- HMNC Holding GmbH1 trial
- and 7 more
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source
Completed
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
NCT06029439· Phase 3· Neumora Therapeutics Inc.· Source
Completed
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine
2023-507942-10-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Completed
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039· Phase 3· Neumora Therapeutics, Inc.· Source
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source
Completed
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· Phase 3· Janssen Cilag International· Source
Completed
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
NCT05729373· Phase 2/3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A 52-week, Open-label Trial of CVL-231 in Adult Participants With Schizophrenia
NCT05443724· Phase 2· Cerevel Therapeutics LLC· Source
Completed
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05304767· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Completed
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157· Phase 3· Neurocrine Biosciences· Source
Completed
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Report an error